Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
OMA Annual Conference 2025
Start date: Apr 23, 2025 End date: Apr 27, 2025
Event Dates: April 23–27, 2025Location: National Harbor, MarylandFocus: Obesity treatment, clinical practices, and patient care advancementsThe Obesity Medicine 2025 conference, hosted by the Obesity Medicine Association (OMA), is a vital opportunity for healthcare professionals dedicated to treating obesity. This annual event offers a comprehensive program featuring the latest research, clinical… View more
Research Area(s) / Expertise: Job title: Professor, Obesity and Stress Hormone Research
Prof Liesbeth van Rossum, MD PhD, is internist-endocrinologist and professor in the field of obesity and stress hormone research at the Erasmus University Medical Center in Rotterdam, Netherlands. Sheis also co-founder of the Obesity Center CGG, an internationally recognised academic centre of obesity management.Prof Van Rossum holds various societal and board positions, amongst the European lead… View more
HRS 25: The TRANSFORM-AF Study
Author(s): Varun Sundaram Added: 11 months ago
HRS 25 - TRANSFORM-AF shows patients with atrial fibrillation and obesity treated with a GLP-1 RA experienced a reduction in atrial fibrillation (AF)-related events.We are joined by Dr Varun Sundaram (Case Western Reserve University, US) to discuss the findings from the TRANSFORM-AF Study, which aimed to determine whether GLP-1 RAs could reduce the burden of AF in patients with both AF and… View more

Cardiovascular Kidney Metabolic

Electrophysiology & Arrhythmia
HFSA 24: STEP-HFpEF: Exercise Function and Frailty Status
Author(s): Mikhail Kosiborod Added: 1 year ago
HFSA 24 - We are joined virtually by Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss findings from the STEP-HFpEF trial programme in regard to the efficacy of semaglutide according to frailty status, and exercise function at baseline.Interview Questions:1. Could you remind us of the importance of STEP-HFpEF2. What was the study design and patient population?3. What… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Maternal Cardiac Function in Pregnancies With Metabolic Disorders
Author(s): Deesha Patel , Makrina D Savvidou Added: 1 year ago

Imaging & Diagnostics

Prevention & Chronic Conditions
HFA 24 Late-Breaker Wrap Up with Dr Van Spall & Dr Petrie
Author(s): Harriette Van Spall , Mark Petrie Added: 1 year ago
HFA 2024 — Join experts, Dr Harriette Van Spall (McMaster University, CA) and Dr Mark Petrie (University of Glasgow, UK) for an insightful wrap up of the novel data presented at 2024's Heart Failure Congress.00:24 - STEP HFpEF Programme: Semaglutide 2.4 mg and NTproBNP in obesity-related HFpEF & Semaglutide therapy and diuretic use in obesity-related HFpEF02:20 - EMPACT-MI: The effect of… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Research Area(s) / Expertise: Job title: Advocate for Obesity; EPCO Secretary
Susie Birney lives with a food disorder called ARFID; she understands that there is not only one cause for obesity and not one treatment which will always work. Type 2 Diabetes and other co-morbidities have been health barriers for her since her 30’s. Since 2016, Susie has been a patient representative with the ASOI and an Irish representative with ECPO. This led to the start of creating a… View more
ECO 24: Semaglutide in Body Weight & Reversion of Normoglycaemia: STEP 10
Author(s): Barbara McGowan Added: 1 year ago
ECO 2024 — Prof Barbara McGowan (Guy's and St Thomas' Hospital & King's College, UK) joins us to discuss the findings from the STEP 10 trial (NCT05040971, Novo Nordisk).This Phase 3 randomised clinical trial investigated the efficacy and safety of subcutaneous semaglutide 2.4 mg (GLP-1 RA) in 181 participants with obesity (BMI greater than or equal to 30.0 kg/m^2) and prediabetes. The primary… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
EASD 25: EMPIRE-PREVENT: Metabolic Effects of Empagliflozin in Patients at Risk of Heart Failure
Author(s): Camilla Andersen Added: 6 months ago
EASD Congress 2025 - Dr Camilla Andersen (The University of Western Australia, Perth, AU) joins us to discuss findings from the EMPIRE-PREVENT: Metabolic study, investigating the metabolic effects of empagliflozin in elderly and obese patients at high risk of developing heart failure (HF).This randomized controlled trial evaluated 165 patients aged 60–84 years with obesity (BMI >28kg/m²) and… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Research Area(s) / Expertise: Job title: Chief Medical Officer
Dr Lydia Alexander is Chief Medical Officer at Enara Health in San Mateo, California. Dr Alexander earned her medical degree at the UC Davis School of Medicine,Sacramento, California; then completed an internal medicine residency at Kaiser Permanente, followed by a chief residency at Kaiser Hospital, both in California. She is trained as a culinary medicine specialist from Tulane University, New… View more